Kintsugi builds vocal biomarker technology and an enterprise API called KiVA that analyzes 20-second voice clips to detect signs of anxiety, depression, and other mental health conditions. The AI examines audio indicators regardless of language, and the company claims KiVA can identify depression more than four out of five times and flag early warning signs up to a decade ahead of traditional methods. Its dataset was collected from a talk therapy app downloaded more than 100,000 times and is, the company says, 110 times larger than the next-biggest dataset of its kind. Kintsugi shares findings with patients and approved medical professionals through its product. The startup plans to use new funding to scale the business, improve its voice test, and apply its dataset to further research. The company is three years old and is positioned among a growing group of mental health vocal biomarker developers. Kintsugi is an API-first platform for payors, providers, and health systems that augments clinicians with AI to identify, triage, and care for patients at scale. The company develops voice-biomarker based mental-health screening that can detect clinical depression and anxiety from roughly 20 seconds of free-form speech. Kintsugi positions this technology to streamline access to care and close gaps across risk-bearing health systems, claiming it saves time and lives. The startup has received multiple distinctions for its AI technology from the National Science Foundation. The newly raised funds will be used to support enterprise deployments across healthcare payors in clinical call centers, telehealth platforms, and remote patient monitoring apps. Financially, Kintsugi closed an $8.0M seed round in August 2021 to accelerate enterprise commercialization.

Total raised

$28M

Funding rounds

2

Latest round

Series A

Latest activity

Feb 2022